Tyra Biosciences (TYRA)
(Delayed Data from NSDQ)
$22.76 USD
+0.63 (2.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $22.76 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TYRA 22.76 +0.63(2.85%)
Will TYRA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TYRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TYRA
Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?
TYRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price Strength
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet
What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'
Other News for TYRA
Oppenheimer’s top 32 ideas for August-September
Tyra Biosciences a new overweight at Piper Sandler as 'next gen FGFR company'
Brinker upgraded, Snowflake downgraded: Wall Street's top analyst calls
Buy Rating for Tyra Biosciences Backed by TYRA-300’s Potential and FGFR Expertise
Tyra Biosciences initiated with bullish view at Piper Sandler, here's why